Abstract

The General Clinical Research Center at VCU/MCV has long been recognized as one of the school's most important resources. A long history of outstanding clinical research and a stable, supportive environment encourage multidisciplinary teams of investigators to work together on the GCRC. Through this five year competitive renewal application we aim to continue to provide the facilities and resources necessary for the conduct of clinical investigations of the highest quality. Sixty-nine scientific proposals detailed in this application involve more than 100 scientists working in major areas of medical research. These include studies in genetic diseases, diabetes, hypertension, renal diseases, cancer pituitary diseases, obesity, sickle cell disease, liver diseases, and vascular responsiveness. The major clinical disciplines including medicine, ob-gyn, surgery, pediatrics, neurology, and psychiatry are represented with additional studies by pharmacy, medicinal chemistry, and nursing.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000065-37
Application #
2797047
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Program Officer
Mccloskey, Donna J
Project Start
1977-12-01
Project End
2002-11-30
Budget Start
1998-12-01
Budget End
1999-11-30
Support Year
37
Fiscal Year
1999
Total Cost
Indirect Cost

  Institution

Name
Virginia Commonwealth University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298

  Publications

Holkova, Beata; Yazbeck, Victor; Kmieciak, Maciej et al. (2017) A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. Leuk Lymphoma 58:1349-1357
Corey, Kathleen E; Vuppalanchi, Raj; Vos, Miriam et al. (2015) Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 60:360-7
Eaton, J E; Juran, B D; Atkinson, E J et al. (2015) A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease. Aliment Pharmacol Ther 41:980-90
Worthington Jr, Everett L; Berry, Jack W; Hook, Joshua N et al. (2015) Forgiveness-reconciliation and communication-conflict-resolution interventions versus retested controls in early married couples. J Couns Psychol 62:14-27
Holkova, Beata; Kmieciak, Maciej; Perkins, E Brent et al. (2014) Phase I trial of bortezomib (PS-341; NSC 681239) and ""nonhybrid"" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res 20:5652-62
Poklepovic, Andrew; Youssefian, Leena E; Youseffian, Leena et al. (2013) Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma. Invest New Drugs 31:937-42
Holkova, Beata; Supko, Jeffrey G; Ames, Matthew M et al. (2013) A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. Clin Cancer Res 19:1873-83
Lo, D J; Farris, A B; Song, M et al. (2013) Inhibition of ?v?6 promotes acute renal allograft rejection in nonhuman primates. Am J Transplant 13:3085-93
Jones, Robert; Vuky, Jacqueline; Elliott, Tony et al. (2013) Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. Invest New Drugs 31:1001-7
Al Hawaj, M A; Martin, E J; Venitz, J et al. (2013) Monitoring rFVIII prophylaxis dosing using global haemostasis assays. Haemophilia 19:409-14

Showing the most recent 10 out of 367 publications